[2021] Vaginal Fungi Infections Treatment Market Is Expected to Reach US$ 1,420.1 Million at a 5.3% CAGR By 2027

SEATTLE, April 14, 2021, (PHARMIWEB) — Global Vaginal Fungi Infections Treatment Market

Overview:

Vaginal fungi infections, also known as candidiasis, is a common condition. Due to the increase in imbalance of bacterial and yeast changes, the fungal cells multiply, which may lead to vaginal fungal infection. Some of the symptoms of this infection are itching, swelling, whitish-gray and clumpy vaginal discharge, irritation, etc. The most common treatment for this infection are ointments or antifungal creams.

The global vaginal fungi infections treatment market is expected to be valued at US$ 987.2 million in 2020 and is expected to exhibit a CAGR of 5.3% during the forecast period (2020-2027).

To learn more about this report, request a sample copy*
* The sample copy includes: Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.

Request a sample copy of this report@ https://www.coherentmarketinsights.com/insight/request-sample/4271

Covid-19 Impact:

The outbreak of COVID-19 has adversely affected many countries due to the lockdown imposed by governments to prevent the spread of the virus. The pandemic has also hampered the production, development, and supply of drugs and other healthcare products, as well as the growth of the global vaginal fungi infections treatment market.

As a result, many orthopedic doctors were deployed to monitor patients suffering from coronavirus infection. Moreover, there has been an increase in the manufacture of medicines and research and development to treat such patients.

Drivers:

Increasing product launches and rising product approvals are expected to drive growth of the global vaginal fungi infections treatment market over the forecast period. For instance, in December 2016, Dr. Reddy’s Laboratories announced the launch of Nystatin and Triamcinolone Acetonide Cream, USP, in the U.S. market, approved by the Food & Drug Administration (FDA). It is the generic equivalent of Nystatin and Triamcinolone Acetonide Cream, USP 100,000 units/g- 0.1% manufactured by Taro Pharmaceuticals USA Inc.

Moreover, key players in the market are adopting various strategies, such as business expansion, to strengthen their market position, which, in turn, is expected to propel the global vaginal fungi infections treatment market growth. For instance, in June 2016, Valeant Canada, a subsidiary of Bausch Health Companies Inc. announced that it is expanding its manufacturing and export capacity in Canada.

Restraints:

Increasing adoption of alternative therapies is expected to hinder growth of the global vaginal fungi infections treatment market.

Market Taxonomy:

By Drug Type

• Flucytosine
• Nystatin
• Fluconazole

By Route of Administration

• Topical
• Oral

By Distribution Channel

• Online Pharmacies
• Retail Pharmacies
• Hospital Pharmacies

By Region

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East and Africa

Access research reports that are tailored specifically for you and your organization in order to explore practical growth strategies and recommendations
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4271

Regional Insights:

North America is expected to witness substantial growth in the global vaginal fungi infection treatment market due to the increasing prevalence of recurrent vulvovaginal candidiasis in the region. According to The Lancet, an article published in August 2018, reports that there were 3,775 and 3,897 base case prevalence per 100,000 females in the U.S. and Canada respectively.

Competitive Section:

Key players operating in the global vaginal fungi infections treatment market are Bausch Health Companies Inc, Pfizer Inc., ANI Pharmaceuticals, Inc., Lupin Limited, Hikma Pharmaceuticals Plc., Mycovia Pharmaceuticals, Unique Pharmaceuticals, Glenmark Pharmaceuticals Limited, PEPTONIC medical AB, Dr. Reddy’s Laboratories, Aurobindo Pharma Limited, and SCYNEXIS, Inc.

In February 2019, Aurobindo Pharma Limited acquired commercial operations and certain supporting infrastructure of Apotex Inc. in five European countries.

View Press Release For More Information @ https://www.coherentmarketinsights.com/press-release/vaginal-fungi-infections-treatment-market-3534

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837